postpartum%20hemorrhage
POSTPARTUM HEMORRHAGE
Postpartum hemorrhage is defined as blood loss of ≥500 mL for vaginal delivery or 1000 mL for abdominal (Caesarean) delivery after completion of the 3rd stage of labor.
Another proposed definition is a 10% fall in hematocrit value.
Since the clinical estimation of the amount of blood loss is typically inaccurate, the diagnosis of postpartum hemorrhage remains a subjective clinical assessment of the amount of blood loss that jeopardizes a woman's hemodynamic stability.
Postpartum hemorrhage may produce hemodynamic instability during the 1st 24 hours after delivery.

Monitoring

Monitor Response to Treatment

  • Sensorium
  • Vital signs
  • Urine output
    • A urine output of >30 mL/hr is an objective sign of adequate renal perfusion
  • Complete blood count (CBC), coagulation
    • Blood sample is drawn to assess hematologic and metabolic profile, electrolytes, coagulation, acid-base oxygenation status
  • Evaluate tissue perfusion
    • Measure serum lactate and base deficit 
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Elaine Soliven, 12 Jan 2018
Use of metformin during the first trimester of pregnancy showed no significant maternal or foetal adverse outcomes in women with gestational diabetes mellitus (GDM), according to a study presented at IDF 2017.
Roshini Claire Anthony, 12 Jan 2018

The use of a cervical pessary may reduce the risk of preterm birth in women with singleton pregnancies and short cervical length, according to a single-centre study from Italy.

26 Feb 2017
Placement of cervical pessary in women with short cervices and singleton pregnancies does not lower the risk of having preterm births, according to the results of a meta-analysis.
Roshini Claire Anthony, 07 Sep 2016

Estrogen receptor α (ESR1) mutations Y537S and D538G are associated with reduced overall survival (OS) in patients with human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer, according to findings of a secondary analysis of the BOLERO-2* clinical trial.